After PM-Carney meet, Canada names consul general in Mumbai
This is the first diplomatic appointment by Canada here since the expulsion of over 40 Canadian diplomats by India after the row over Canadian allegations - under former PM Justin Trudeau - that the Indian government orchestrated the killing of Khalistan separatist on Canadian soil.
Tired of too many ads? go ad free now
The two countries are also likely to soon reappoint high commissioners, in line with the understanding reached earlier this year. According to official sources, they have already exchanged the names of the high commissioners.
The development follows PM Modi's meeting with his counterpart Mark Carney on the sidelines of the G7 Summit in Kananaskis, Alberta, in June. The leaders had underlined the need to pursue a constructive and balanced partnership grounded in "mutual respect for concerns and sensitivities, strong people-to-people ties, and growing economic complementarities".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
US tariffs should not be cause for disengaging from trade talks, blocs
The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —
News18
35 minutes ago
- News18
Following are the top foreign stories at 2100 hours
FGN6 BANGLA-HASINA ****Bangladesh tribunal commences trial of deposed PM Hasina over crimes against humanity Dhaka: Bangladesh's International Crimes Tribunal (ICT) on Sunday commenced the trial of deposed Prime Minister Sheikh Hasina in absentia over crimes against humanity related to the violent suppression of the 2024 student-led protests.**** FGN17 BANGLA-RALLIES ****B'desh: BNP's student wing, NCP hold rallies ahead of July Uprising anniversary Dhaka: Activists of the National Citizen Party and the BNP's student wing held separate rallies in Bangladesh on Sunday ahead of the first anniversary of the July Uprising that toppled the Sheikh Hasina-led government on August 5 last year.**** FGN9 PAK-IRAN-NUCLEAR ****Pakistan supports Iran's right to develop nuclear capability for peaceful purposes Islamabad: Pakistan on Sunday supported Iran's right to develop nuclear capability for peaceful purposes, as the two sides signed several agreements to expand cooperation in multiple fields.**** FGN8 PAK-IRAN-TRADE ****Pakistan: Iran decide to increase bilateral trade to USD 8 billion annually Islamabad: Pakistan and Iran agreed on Sunday to increase bilateral trade to USD 8 billion annually, taking advantage of their geography and the 'discount of distance," as trade ministers from the two countries held discussions to deepen economic and political ties.**** FGN14 US-INDIANS-ACCIDENT ****Four senior Indian-origin persons killed in car crash in West Virginia New York: In a tragic incident, four senior Indian-origin persons were killed in a car crash in West Virginia, authorities said on Sunday.
India Today
42 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch
